



## Clinical trial results: Taurine and Painful Diabetic Neuropathy Summary

EudraCT number	2005-004196-37
Trial protocol	GB
Global end of trial date	21 August 2014

### Results information

Result version number	v1 (current)
This version publication date	29 August 2020
First version publication date	29 August 2020
Summary attachment (see zip file)	Summary 2005-004196-37 (EudraCT study letter 18.09.19.pdf)

### Trial information

#### Trial identification

Sponsor protocol code	RG_05-126
-----------------------	-----------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	University of Birmingham
Sponsor organisation address	Edgbaston, Birmingham, United Kingdom, B15 2TT
Public contact	Research Governance Team, University of Birmingham, researchgovernance@contacts.bham.ac.uk
Scientific contact	Research Governance Team, University of Birmingham, researchgovernance@contacts.bham.ac.uk

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	21 August 2014
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	21 August 2014
Was the trial ended prematurely?	Yes

Notes:

## General information about the trial

Main objective of the trial:

This study aims to determine whether neuropathic pain in diabetes can be decreased with the use of taurine through subjective pain measures and electrophysiological measurements.

Protection of trial subjects:

Inclusion criteria: 1. Type 1/type 2 diabetes, as defined by the WHO Classification.2.Duration of diabetes of at least 5 years.3. HbA1c should be <9% with <1% fluctuation of HbA1c levels over the past 6 months.4.Age between 18 and 70 years.

5.Women of childbearing potential must be using an acceptable method of contraception to prevent pregnancy when they are enrolled in the study and must agree to continue to practice an acceptable method of contraception for the duration of their participation in the study.

6.Must meet the specified criteria for painful DN and have no risk factors for other causes for neuropathy. 7.Willingness to sign the Centre for Research Ethics Committee (COREC) approved consent form

Exclusion criteria:1.Nursing mothers, pregnant women (excluded by a negative pregnancy test).2.History of drug or alcohol dependence in the last 5 years 3.Pre-existing cardiovascular disease. Hypoxemic disease. 4.Severe systemic disease other than diabetes which has as a recognized complication neuropathy or severe chronic pain 5.Symptoms of neuropathic pain in the upper limbs alone 6.Significant changes in skin conditions in the areas to be tested which could alter sensation.

7.Previous history of neuropathic foot ulceration or Charcot arthropathy 8.Taking medications that could affect symptoms of painful DN except paracetamol (up to 4 g/d) or aspirin (up to 325 mg/d). 9. Experiencing an increase in pain after analgesic medication washout to levels which would, in the view of the principal investigator (PI), require prohibited analgesic therapy within a 12 wk period. 10.Creatinine clearance is less than 70 ml/min or have significant hepatic disease (AST, ALT, γGT >2 times upper limit for normal). 11.History of previous kidney, pancreas or cardiac transplantation.12, Serious or unstable medical or psychological state that may interfere with study participation.13. Taking other drugs/insulin within 3 months of starting study. 14. Morbidly obese.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	31 October 2006
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	United Kingdom: 88888
Worldwide total number of subjects	88888
EEA total number of subjects	88888

Notes:

<b>Subjects enrolled per age group</b>	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	88888

## Subject disposition

### Recruitment

Recruitment details:

After a regulatory inspection the trial was closed as the inspection identified issues with data integrity. Our Clinical Trials Oversight Committee have made a decision that these results should not be in the public domain. For the purposes of data entry 88888 is referring to not applicable due to the data integrity issues

### Pre-assignment

Screening details:

After a regulatory inspection the trial was closed as the inspection identified issues with data integrity. Our Clinical Trials Oversight Committee have made a decision that these results should not be in the public domain. For the purposes of data entry 88888 is referring to not applicable due to the data integrity issues

### Period 1

Period 1 title	Overall (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Blinding implementation details:

After a regulatory inspection the trial was closed as the inspection identified issues with data integrity. Our Clinical Trials Oversight Committee have made a decision that these results should not be in the public domain. For the purposes of data entry 88888 is referring to not applicable due to the data integrity issues

### Arms

Arm title	Overall
-----------	---------

Arm description:

After a regulatory inspection the trial was closed as the inspection identified issues with data integrity. Our Clinical Trials Oversight Committee have made a decision that these results should not be in the public domain. For the purposes of data entry 88888 is referring to not applicable due to the data integrity issues

Arm type	n/a
Investigational medicinal product name	Taurine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

After a regulatory inspection the trial was closed as the inspection identified issues with data integrity. Our Clinical Trials Oversight Committee have made a decision that these results should not be in the public domain. For the purposes of data entry 88888 is referring to not applicable due to the data integrity issues

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

After a regulatory inspection the trial was closed as the inspection identified issues with data integrity. Our Clinical Trials Oversight Committee have made a decision that these results should not be in the public domain. For the purposes of data entry 88888 is referring to not applicable due to the data integrity issues

<b>Number of subjects in period 1</b>	Overall
Started	88888
Completed	88888

## Baseline characteristics

### Reporting groups

Reporting group title	Overall
-----------------------	---------

Reporting group description:

After a regulatory inspection the trial was closed as the inspection identified issues with data integrity. Our Clinical Trials Oversight Committee have made a decision that these results should not be in the public domain. For the purposes of data entry 88888 is referring to not applicable due to the data integrity issues

Reporting group values	Overall	Total	
Number of subjects	88888	88888	
Age categorical			
After a regulatory inspection the trial was closed as the inspection identified issues with data integrity. Our Clinical Trials Oversight Committee have made a decision that these results should not be in the public domain. For the purposes of data entry 88888 is referring to not applicable due to the data integrity issues			
Units: Subjects			
Not applicable	88888	88888	
Gender categorical			
After a regulatory inspection the trial was closed as the inspection identified issues with data integrity. Our Clinical Trials Oversight Committee have made a decision that these results should not be in the public domain. For the purposes of data entry 88888 is referring to not applicable due to the data integrity issues			
Units: Subjects			
Not applicable	88888	88888	

## End points

### End points reporting groups

Reporting group title	Overall
Reporting group description: After a regulatory inspection the trial was closed as the inspection identified issues with data integrity. Our Clinical Trials Oversight Committee have made a decision that these results should not be in the public domain. For the purposes of data entry 88888 is referring to not applicable due to the data integrity issues	

### Primary: Not applicable

End point title	Not applicable <sup>[1]</sup>
End point description: After a regulatory inspection the trial was closed as the inspection identified issues with data integrity. Our Clinical Trials Oversight Committee have made a decision that these results should not be in the public domain. For the purposes of data entry 88888 is referring to not applicable due to the data integrity issues	
End point type	Primary
End point timeframe: After a regulatory inspection the trial was closed as the inspection identified issues with data integrity. Our Clinical Trials Oversight Committee have made a decision that these results should not be in the public domain.	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses have been specified as the trial was terminated early. After a regulatory inspection the trial was closed as the inspection identified issues with data integrity. Our Clinical Trials Oversight Committee have made a decision that these results should not be in the public domain. For the purposes of data entry 88888 is referring to not applicable due to the data integrity issues.

<b>End point values</b>	Overall			
Subject group type	Reporting group			
Number of subjects analysed	88888 <sup>[2]</sup>			
Units: n/a	88888			

Notes:

[2] - 88888 is referring to not applicable due to the data integrity issues

### Statistical analyses

No statistical analyses for this end point

## Adverse events

---

### Adverse events information<sup>[1]</sup>

---

Timeframe for reporting adverse events:

After a regulatory inspection the trial was closed as the inspection identified issues with data integrity. Our Clinical Trials Oversight Committee have made a decision that these results should not be in the public domain.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	n/a
Dictionary version	0

Frequency threshold for reporting non-serious adverse events: 0 %

---

#### Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.

Justification: Justification - No adverse events have been specified as the trial was terminated early. After a regulatory inspection the trial was closed as the inspection identified issues with data integrity. Our Clinical Trials Oversight Committee have made a decision that these results should not be in the public domain. For the purposes of data entry 88888 is referring to not applicable due to the data integrity issues.



## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

After a regulatory inspection the trial was closed as the inspection identified issues with data integrity. Our Clinical Trials Oversight Committee have made a decision that these results should not be in the public domain.
---

Notes: